Abstract:Abstract Background: Germline mutations in BRCA1, BRCA2 and other genes predispose to high risks of breast cancer. Genetic testing for germline mutations in BRCA1 and BRCA2 has been widely used in women with severe family history of breast or ovarian cancer in many western countries. However, in China, hereditary breast cancer associated genes and their mutation types remain unclear. So far, there's no recommended guidelines for high-risk populations. Next-Generation Sequencing (NGS) technology has been proved to detect all classes of mutations cost-effectively. Here we describe the first study of germline mutations in 196 genes in Chinese breast cancer families using NGS. Methods: Breast cancer patients were consecutively enrolled at diagnosis in our hospital between 2011-2012. Inclusion criteria were as follows: Firstly, breast cancer patients are Shanghai natives; secondly, breast cancer patients aged 35 or younger had at least another family member with any type of cancer or those between 35 and 50 years had ≥2 family members with cancer on same side of family or those above 50 years had ≥3 family members with cancer on same side of family. A total of 196 genes were tested and they included two parts. One hundred and twenty-two genes selected were associated with 54 hereditary cancer syndromes and another 74 genes were cancer susceptibility genes proved by researches published on Pubmed up to 2012. Blood samples were collected and genomic DNA were subjected to targeted capture using the Agilent SureSelect DNA kit and sequencing of exons and flanking regions corresponding to 196 genes using the Illumina HiSeq 2000 platform. All classes of genomic alterations were detected. The study was approved by the Scientific and Ethical Committee of the Cancer Hospital of Fudan University. All participants provided informed consent. Results: Eighty-six breast cancer patients met our inclusion criteria were enrolled in our study. The 86 families totally harbored 456 cancers, mainly including 206(45.2%) breast cancers, 45(9.9%) colorectal carcinomas, 38(8.3%) lung cancers, 36(7.9%) gastric cancers, 28(6.1%) hepatic carcinomas and 17(3.7%) ovarian cancers. A total of 66 germline mutations were detected in 29 genes of 46 probands, including 18 BRCA1 or BRCA2 mutations and one recurrent mutation in each gene, one novel TP53 mutations, one germline mutation in RAD50, PALB2, FANCD2, FANCI, RAD51C, SLX4/FANCP, etc. All of these genes were previously reported in hereditary breast cancer. Of women with germline mutations, the mean age at first primary breast cancer diagnosis was 39.6 y and 10(21.7%) of them had bilateral breast cancer. As for all genomic rearrangements, bioinformatics analysis is in process. Conclusion: This is the first study to report the spectrum of germline mutations in 196 hereditary cancer associated genes in Chinese familial breast cancer patients regardless of cancer types of family members. It will give us a reference for carrying out genetic counseling in Chinese breast cancer families. At the same time, NGS is an effective method to test many genes simultaneously at low cost. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-07-06.

Clinical Validation of an NGS-based Assay for the Detection of BRCA1 and BRCA2 Variants in Chinese Patients with Breast Cancer or Ovarian Cancer

Prevalence and Reclassification of BRCA1 and BRCA2 Variants in a Large, Unselected Chinese Han Breast Cancer Cohort

Clinical Validation of an NGS-based Assay for Detecting Multiple Genomic Alterations in Chinese Patients with Non-Small Cell Lung Cancer

Reliable assessment of BRCA1 and BRCA2 germline variants by next-generation sequencing: a multicenter study

The landscape of BRCA1 and BRCA2 alterations in Chinese ovarian cancer patients.

Assessing the Variations in Breast/Ovarian Cancer Risk for Chinese BRCA1/2 Carriers

Retrospective reinterpretation and reclassification of BRCA1/2 variants from Chinese population

Characteristics of Germline Non-BRCA Mutation Status of High-Risk Breast Cancer Patients in China and Correlation with High-Risk Factors and Multigene Testing Suggestions

A MALDI-TOF mass spectrometry-based method for detection of copy number variations in BRCA1 and BRCA2 genes

Abstract 4289: Detection of Germline Large Genomic Rearrangements in BRCA1/2 Genes by a Capture-Based NGS Panel Reveals Its Contribution to Chinese Patients with Solid Tumors

Retrospective analysis of non-BRCA gene pathogenicity variation in Chinese patients with ovarian cancer.

Gene Panel Sequencing in a Chinese High-risk Breast Cancer Cohort

Performance Validation of an Amplicon-Based Targeted Next-Generation Sequencing Assay and Mutation Profiling of 648 Chinese Colorectal Cancer Patients.

Multicenter Cross-Sectional Screening of the BRCA Gene for Chinese High Hereditary Risk Breast Cancer Populations

The Spectrum of BRCA Mutations and Characteristics of BRCA-associated Breast Cancers in China: Screening of 2,991 Patients and 1,043 Controls by Next-Generation Sequencing.

Abstract P2-07-06: Detection of germline mutations in 196 genes in Chinese breast cancer families using targeted capture and next-generation sequencing

Analysis of BRCA1/2 Mutation Spectrum and Prevalence in Unselected Chinese Breast Cancer Patients by Next-Generation Sequencing

Discovery of Rare Coding Variants in OGDHL and BRCA2 in Relation to Breast Cancer Risk in Chinese Women.

Identification of Recurrent Variants in BRCA1 and BRCA2 Across Multiple Cancers in the Chinese Population

BRCA Germline Mutations in an Unselected Nationwide Cohort of Chinese Patients with Ovarian Cancer and Healthy Controls

Application of next-generation sequencing in detection of breast cancer susceptibility genes BRCA1/2,TP53 and PTEN germline mutation